Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Discloses Dako Earnings

NEW YORK (GenomeWeb News) – Through eight months ending May 31, 2012, Dako posted $242 million in revenues, Agilent Technologies disclosed in a regulatory filing after the close of the market on Wednesday, which also disclosed Dako's earnings for full-year 2011 and for the six months ended March 31.

Agilent completed its $2.2 billion purchase of the Danish cancer diagnostics company in June.

In a document filed with the US Securities and Exchange Commission on Wednesday, Agilent said that Dako had a net loss of $61 million on a GAAP basis for the eight months ended May 31. R&D spending during the period totaled $37 million and SG&A costs were $100 million.

During the six months ended March 31, Dako posted revenues of $183 million and a net loss of $23 million. It spent $24 million on R&D and $76 million on SG&A. In full-year 2011, the firm had a loss of $43 million on revenues of $361 million. R&D spending was $51 million for FY 2011, while SG&A spending was $155 million.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.